Tag: Results

Clearmind Medicine (CMND) Reports Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Clearmind Medicine Inc. (NASDAQ: CMND) today announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a new pre-clinical trial (the “trial” ) resulted in …

Clinical translation of stem cell therapy for spinal cord injury still premature: results from a single-arm meta-analysis based on 62 clinical trials | BMC Medicine

James SL, Theadom A, Ellenbogen RG, Bannick MS, Montjoy-Venning W, Lucchesi LR, et al. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):56–87. Article  Google Scholar  Flack JA, Sharma KD, Xie JY. Delving into the recent advancements of spinal cord injury …

Risk of hip fracture in meat-eaters, pescatarians, and vegetarians: results from the UK Women’s Cohort Study | BMC Medicine

Dhanwal DK, Dennison EM, Harvey NC, Cooper C. Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop. 2011;45(1):15–22. PubMed  PubMed Central  Article  Google Scholar  Veronese N, Maggi S. Epidemiology and social costs of hip fracture. Injury. 2018;49(8):1458–60. Read morePoultry Medication and Vaccines Market Dimension 2021PubMed  Article  Google Scholar  Jennison T, Brinsden M. Fracture admission trends in England over a …

Lilly’s SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight

Detailed results from Lilly’s first phase 3 trial in obesity or overweight presented at the American Diabetes Association’s® 82nd Scientific Sessions® and simultaneously published in NEJM INDIANAPOLIS, June 4, 2022 /PRNewswire/ — Detailed results from Eli Lilly and Company’s (NYSE: LLY) phase 3 SURMOUNT-1 clinical trial evaluating tirzepatide for the treatment of obesity or overweight were simultaneously published today in The New …

Galmed Pharmaceuticals : Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine – Form 6-K

Results from Galmed’s Phase 2b ARREST study with aramchol published in Nature Medicine – The data complements the growing body of clinical and scientific evidence demonstrating the therapeutic potential of aramchol, a stearoyl-CoA desaturase (SCD 1) down regulator, for the treatment of NASH and fibrosis – A Phase 3 program is currently underway with a higher daily dose of aramchol …

Cat Financial Announces Second-Quarter 2021 Results

NASHVILLE, Tenn., July 30, 2021 / PRNewswire / – Cat Financial reported revenue of $ 646 million, An increase from $ 5 million, or 1% compared to the second quarter of 2020. The profit for the second quarter of 2021 was $ 142 million, An increase from $ 83 million, or 141% compared to Q2 2020. The increase in sales …

The surprising results of my rescue dog’s DNA test

Meet my dog ​​Dobby. Dobby was rescued from a Connecticut animal shelter in the United States by my partner in 2018, and his breed has always been a source of baffled entertainment to us. His big ears made us think of Corgis and Pharaoh Hounds, but his physique was small and his long, skinny legs seemed out of place with …

AusCann experiences medicinal hashish canine trial outcomes promising | The Examiner

News, Local News, Medical Cannabis, Dogs, Pain Relief, AusCann, CannPaul, Tasmania, USA, Study There is hope for painful boobs, limping Labradoodles and fighting Shih Tzus. A Tasmania-affiliated company has reported promising results from a US study of a cannabis-based pain reliever for dogs. Perth-based AusCann Group Holdings Limited, which sources cannabis resin from Tasmanian alkaloids, announced that its acquisition of …

New England Journal of Drugs Publishes 24-Week Outcomes from Section Three Research Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis

NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs …

New Veterinary Advertising Efficiency Examine Delivers Surprising Outcomes

GeniusVets suppresses competition in new marketing results study GeniusVets is redefining dominance by outperforming the rest of the industry combined The best way to understand performance is compared to others … The study showed that our top 10 customers received more web traffic than the top 10 customers of our top 10 competitors put together > 30%. “ Read moreGlobal …